| 000 | 01175 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250515134927.0 | ||
| 264 | 0 | _c20081216 | |
| 008 | 200812s 0 0 eng d | ||
| 022 | _a1462-0332 | ||
| 024 | 7 |
_a10.1093/rheumatology/ken353 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDeighton, C | |
| 245 | 0 | 0 |
_aWhy do the French get much greater access to anti-TNF than the British? Vive la difference? Pas necessairement. _h[electronic resource] |
| 260 |
_bRheumatology (Oxford, England) _cNov 2008 |
||
| 300 |
_a1600-2 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Editorial; Comment | ||
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aFrance |
| 650 | 0 | 4 | _aGuideline Adherence |
| 650 | 0 | 4 | _aHealthcare Disparities |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPatient Selection |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 650 | 0 | 4 | _aUnited Kingdom |
| 700 | 1 | _aHyrich, K | |
| 773 | 0 |
_tRheumatology (Oxford, England) _gvol. 47 _gno. 11 _gp. 1600-2 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/rheumatology/ken353 _zAvailable from publisher's website |
| 999 |
_c18253085 _d18253085 |
||